• ELTX is trading at $2.98 (6.4% up) in after-hours trading, rebounding from a steep regular-session decline to $2.80.
  • Elicio Therapeutics announced the closing of a $15 million registered direct offering on July 7, 2026.
  • The offering involved selling 4,380,313 shares of common stock to new institutional investors and an existing shareholder.
  • Proceeds are intended to fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC, pipeline, and general corporate purposes.